Ligand Receives $4 Million from Expansion of Two OmniAb® License Agreements
Ligand Reports First Quarter 2016 Financial Results
Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 Million
Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences
Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP
Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics
Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection
Ligand Reports Fourth Quarter and Full Year 2015 Financial Results
Ligand Enters Into OmniAb® Platform License Agreement with Tizona Therapeutics
